The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2019 | Lymphoma: pre-treatment PET scans
Paolo Strati, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, highlights the key findings from a trial looking at pre-treatment PET scans of 346 patients with advanced stage fully grown lymphoma; observing that generally those with high SUVmax had a shorter overall survival rate, independent of the type of treatment used. Speaking from the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting in Chicago, IL, Dr Strati demonstrates the need to determine the prognostic value of the pre-treatment PET scans and SUVmax measurement.
